Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

DCTH vs PMI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 6 – 0 PMI Matrix Metrics: DCTH 8 – 2 PMI

As of Nov 19, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.4/100 (SELL) at $19.24 (70.3x Forward P/E, 5.2% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin).

  • Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. DCTH 35.4/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -248.1% operating margin) and revenue trajectory (+70.7% vs. +38.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs PMI
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.24
-2.34% 1D
Market Cap $685.3M
TTM Revenue $110M
Forward P/E 70.3x
Beta / 30D Vol 1.64β · 130% Vol
Unified Composite Score
35.4 / 100 SELL
Tech 50.0 Fund 36.0 Flow 73.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.3% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $17.12 · SMA50: $16.16
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62

6-Pillar Scorecard Institutional Category Breakdown (DCTH 6 – 0 PMI)

Columns: Metric · DCTH · PMI
1. Valuation Multiples DCTH
Forward P/E 70.3x N/M
Trailing P/E 123.1x 2.9x
PEG Ratio 1.60x N/M
EV / Revenue 5.7x 3.2x
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% +38.6%
Earnings Growth (YoY) +750.0% +0.0%
TTM Revenue (USD) $110M $6.3M
Market Cap $685.3M $17.1M
3. Profitability & Quality DCTH
Gross Margin 87.6% 18.6%
Operating Margin 5.2% -248.1%
Net Profit Margin 6.0% 0.0%
Return on Equity (ROE) 5.4% 0.0%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M -$17M
Cash Flow Margin 18.3% N/A
Net Cash / Leverage $53M Net Cash $3.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 73.8% (29th %ile) N/A (N/A)
Put/Call OI Skew 0.21x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (8) vs PMI (2)
Institutional Metric DCTH PMI Criterion Row Edge
Market Capitalization
Scale
$685.3M $17.1M Larger Scale DCTH
Trailing P/E Ratio
Valuation
123.1x 2.9x Lower Multiple PMI
Forward P/E Ratio
Valuation
70.3x N/M Lower Multiple DCTH
Revenue Growth (YoY)
Growth
+70.7% +38.6% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% -248.1% Higher Margin DCTH
Net Profit Margin
Profitability
6.0% 0.0% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% 0.0% Higher ROE DCTH
52-Week Range Position
Momentum
77% ($8–$23) 34% ($0–$18) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.64β · 130% Vol 54.06β · 134% Vol Lower Realized Risk DCTH
Unified Institutional Score
Composite Signal
35.4 / 100 (SELL) 48.4 / 100 (HOLD) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$110M $6.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% 18.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 5.7x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) -$17M ($3.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +65.46 pp
DCTH: +30.88% · PMI: -34.58%
3M Horizon PMI +84.01 pp
DCTH: +12.25% · PMI: +96.26%
6M Horizon PMI +3369.67 pp
DCTH: +69.66% · PMI: +3439.33%
1Y Horizon PMI +25.6 pp
DCTH: +122.43% · PMI: +148.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DCTH Revenue PMI Revenue DCTH Op. Margin PMI Op. Margin Margin Leader
FY2013 $0M N/A -4179.6% N/A DCTH
FY2014 $0M N/A -1805.8% N/A DCTH
FY2015 $0M N/A -870.6% N/A DCTH
FY2021 $0M N/A -690.0% N/A DCTH
FY2022 $0M N/A -1245.1% N/A DCTH
FY2023 $0M N/A -1849.0% N/A DCTH
FY2024 $40M $0M -33.4% -312.3% DCTH
FY2025 $90M $0M 0.8% -268.4% DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
69d in phase · OBV DISTRIBUTION
Current IV 73.8%
IV Percentile 29th %ile
Put/Call OI Skew 0.21x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $685.3M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs PMI Key Questions & Quantitative Answers

As of Nov 19, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.4/100 (SELL) at $19.24 (70.3x Forward P/E, 5.2% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. DCTH 35.4/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -248.1% operating margin) and revenue trajectory (+70.7% vs. +38.6% YoY).

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), DCTH cumulative revenue shifted +125.0% while PMI shifted N/A. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.

DCTH screens cheaper on headline valuation multiples. DCTH trades at 70.3x Forward P/E, 123.1x Trailing P/E, 1.60x PEG, and 5.7x EV/Revenue (18.3% FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus PMI (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 73.8% implied volatility (29th %ile, Balanced (25th–60th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.64β · 130% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.